BLTE - Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting | Benzinga
- Tinlarebant is Belite Bio's orally administered tablet intended to slow disease progression in patients affected with Stargardt Disease (STGD1) and Geographic Atrophy (GA) in advanced Dry Age-related Macular Degeneration (Dry AMD)
- Data from a 24-month Phase 2 trial in adolescent STGD1 subjects showed a sustained lower atrophic lesion growth in Tinlarebant-treated subjects compared to ProgStar participants possessing similar baseline characteristics (aged ?18 years) (p<0.001)
- In the Phase 2 trial, 42% of Tinlarebant-treated subjects (5 out of 12) did not develop atrophic retinal lesions during the 24-month treatment period
- Enrollment of a pivotal global Phase 3 trial of Tinlarebant in adolescent STGD1 subjects ("DRAGON") has been completed with 104 subjects across 11 countries with interim data expected in 4Q 2024
- A Phase 2/3 trial in adolescent STGD1 ("DRAGON II") and a global Phase 3 trial in GA ("PHOENIX") are ongoing
SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio" or the "Company"), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced the presentation at Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2024) being held May 5 – 9, 2024, in Seattle, WA.
Details of the presentation are as follows:
- Presentation Number: 1026
- Presentation Title: Safety, Tolerability, and Efficacy of Tinlarebant from the 24-Month Phase 2 study in Adolescent Patients Affected by Stargardt Disease
- Session Date/Start Time: May 5, 2024 from 3:45 PM to 4:00 PM PT
- Location: Tahoma 3 (Seattle Convention Center - Arch Building)
- Presenting Author: Dr. John Grigg, MBBS
About Tinlarebant (a/k/a LBS-008)
Tinlarebant is a novel oral therapy that is intended to reduce the accumulation of vitamin A-based toxins (known as bisretinoids) that cause ...